NEVRO CORP. (NYSE:NVRO) Files An 8-K Other Events
Item 8.01 Other Events

On November 28, 2016, Nevro Corp. (“Nevro”) announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. The lawsuit, filed in the United States District Court for the Northern District of California, asserts that Boston Scientific is infringing Nevro’s patents covering inventions relating to Nevro’s groundbreaking Senza^® system and HF10^™ therapy. The lawsuit seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney’s fees.

About NEVRO CORP. (NYSE:NVRO)

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

NEVRO CORP. (NYSE:NVRO) Recent Trading Information

NEVRO CORP. (NYSE:NVRO) closed its last trading session down -1.45 at 84.75 with 349,078 shares trading hands.